Affiliation:
1. Department of Veterinary Medical Sciences Alma Mater Studiorum University of Bologna Bologna Italy
2. Clinica Veterinaria dell'Orologio Sasso Marconi (BO) Italy
3. Department of Veterinary Sciences University of Torino Torino Italy
4. Department of Veterinary Medicine and Animal Sciences University of Milan Milan Italy
5. Clinica Veterinaria Gran Sasso Milan Italy
Abstract
ObjectivesTo review clinical characteristics, treatment, outcome and prognostic factors in dogs with solid cancer‐bearing bone metastases.Materials and MethodsRecords were reviewed from dogs with histologically‐proven solid cancer and bone metastases. Clinicopathologic variables, bone metastases characteristics and skeletal‐related events were recorded. Endpoints were time to bone metastases and survival.ResultsFifty dogs were included, 20 of them with synchronous and 30 of them with metachronous bone metastases. In the latter group, median time to diagnosis of bone metastases was 210 days (range, 30 to 1835). Most common primary cancer locations included mammary gland (n=6), spleen (n=5) and tonsil (n=5). Most common histotypes were carcinoma (n=32) and hemangiosarcoma (n=10). Nineteen dogs had multiple bones involvement, with humeri and vertebrae more commonly affected. Twenty‐four dogs received antitumoural therapy, five symptomatic treatment and 21 were not treated. Overall median survival after bone metastases diagnosis was 30 days (range, 11 to 49); 83% of dogs died because of skeletal‐related events. Lack of antitumoural therapy was significantly associated with shorter survival (hazard ratio: 2.7; 95% confidence interval: 1.3 to 5.6) and with increased risk of skeletal‐related death (hazard ratio: 3.3; 95% confidence interval: 1.4 to 7.4). Dogs with endocrine/neuroendocrine tumours (odds ratio: 8.8; 95% confidence interval: 1.2 to 63.9), without appendicular metastases (odds ratio: 5.1; 95% confidence interval: 1.0 to 25.8), without extra‐skeletal metastases (odds ratio: 5.2; 95% confidence interval: 1.1 to 24.5) and receiving antitumoural therapy (odds ratio: 14.8; 95% confidence interval: 1.7 to 131.4) had an increased chance of surviving more than 100 days.Clinical SignificanceBone metastases in dogs with solid cancers are associated with poor prognosis and a high risk of skeletal‐related events. Treatment appears to have an impact on survival.